SI

Sebastien Iva

Chief Executive Officer

Fab'entech

Geneva, Geneva


Contact Information

Email
Unlock
LinkedIn

Company Information

Company
Fab'entech
Industry
pharmaceuticals
Employees
62.0
Seniority
C suite
Annual Revenue
8966000.0
Total Funding
28742300.0
Latest Funding
Debt Financing

Technologies

reCAPTCHA Apache Mobile Friendly Google Tag Manager WordPress.org

Keywords

immunotherapy polyclonal antibody antibodies emergency antidote antitoxin bioterrorism bioweapon poison infectious disease infectious diseases nosocomial emerging epidemic pandemic ebola drug abuse narcotic dependence pharmaceutical manufacturing polyclonal antibodies biodefense solutions emergency treatments viral neutralization toxin neutralization biological threats health security pandemic preparedness covid-19 treatments fabshield technology viral infections emerging infectious diseases clinical trials bioterrorism response fabenflu fabencov nipah virus sarbecoviruses medical countermeasures rapid response health public crises highly purified antibodies risk management antidotes targeted therapies animal rule public health biopharmaceutical development pathogen targeting hospitals emergency response toxic agents virus mutations clinical development stages infectious disease response antibody development supply chain management biotechnology innovation health emergency preparedness european health initiatives therapeutic response medical product pipeline global health initiatives antibody production health crisis management toxins & antidotes bio-production facilities public health collaborations pharmaceuticals medical health care health wellness & fitness hospital & health care logistics & supply chain

Get Full Contact Details

Subscribe to reveal email addresses and export contacts.

View Plans